BACKGROUND: Several lines of evidence have implicated female hormones in the etiology of human brain tumors, meningiomas in particular. PURPOSE: To investigate the relationship between brain tumor development and the hormonal changes manifested during pregnancy and menopause, we analyzed data from female participants in a population-based case-control study of adult brain tumors. This study was conducted in 1987-1988 in the Rhein-Neckar-Odenwald area of the Federal Republic of Germany. METHODS: The study population consisted of 127 women with meningiomas, gliomas, and acoustic neuromas (case patients) and 233 control women who were selected from the general population and frequency-matched by age to the case patients. Information on parity, menopausal status, and previous gynecologic surgeries was obtained through a standardized questionnaire. Case patients and control subjects were compared with the use of the unconditional maximum likelihood estimation of the parameters in a logistic regression model. RESULTS: Our results were not statistically significant; nevertheless, they revealed some interesting trends. No association was found between parity and the development of any of the three histological subtypes of brain tumor (relative risk [RR] = 1.31; 95% confidence interval [CI] = 0.51-2.07). Menopausal women had a greatly reduced risk of developing meningiomas (RR = 0.58; 95% CI = 0.18-1.90), and this effect was most pronounced when menopause had been surgically induced by bilateral oophorectomy (RR = 0.12; 95% CI = 0.01-1.30). Menopausal women had a greater risk of developing gliomas or acoustic neuromas (RR = 1.77; 95% CI = 0.67-4.68), except when menopause was surgically induced, in which case the risk was reduced (RR = 0.33; 95% CI = 0.04-3.09). Oophorectomy after menopause did not appear to influence risk. CONCLUSIONS: Since the onset of menopause is accompanied by cessation of estrogen production, our results support the notion that female hormones play a role in the development of brain tumors.
BACKGROUND: Several lines of evidence have implicated female hormones in the etiology of humanbrain tumors, meningiomas in particular. PURPOSE: To investigate the relationship between brain tumor development and the hormonal changes manifested during pregnancy and menopause, we analyzed data from female participants in a population-based case-control study of adult brain tumors. This study was conducted in 1987-1988 in the Rhein-Neckar-Odenwald area of the Federal Republic of Germany. METHODS: The study population consisted of 127 women with meningiomas, gliomas, and acoustic neuromas (case patients) and 233 control women who were selected from the general population and frequency-matched by age to the case patients. Information on parity, menopausal status, and previous gynecologic surgeries was obtained through a standardized questionnaire. Case patients and control subjects were compared with the use of the unconditional maximum likelihood estimation of the parameters in a logistic regression model. RESULTS: Our results were not statistically significant; nevertheless, they revealed some interesting trends. No association was found between parity and the development of any of the three histological subtypes of brain tumor (relative risk [RR] = 1.31; 95% confidence interval [CI] = 0.51-2.07). Menopausal women had a greatly reduced risk of developing meningiomas (RR = 0.58; 95% CI = 0.18-1.90), and this effect was most pronounced when menopause had been surgically induced by bilateral oophorectomy (RR = 0.12; 95% CI = 0.01-1.30). Menopausal women had a greater risk of developing gliomas or acoustic neuromas (RR = 1.77; 95% CI = 0.67-4.68), except when menopause was surgically induced, in which case the risk was reduced (RR = 0.33; 95% CI = 0.04-3.09). Oophorectomy after menopause did not appear to influence risk. CONCLUSIONS: Since the onset of menopause is accompanied by cessation of estrogen production, our results support the notion that female hormones play a role in the development of brain tumors.
Authors: Tessa A Harland; Jacob L Freeman; Monica Davern; D Jay McCracken; Emma C Celano; Kevin Lillehei; Jeffrey J Olson; D Ryan Ormond Journal: J Neurooncol Date: 2017-10-28 Impact factor: 4.130
Authors: Varun R Kshettry; Quinn T Ostrom; Carol Kruchko; Ossama Al-Mefty; Gene H Barnett; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2015-05-24 Impact factor: 12.300
Authors: Sophia S Wang; Patricia Hartge; Meredith Yeager; Tania Carreón; Avima M Ruder; Martha Linet; Peter D Inskip; Amanda Black; Ann W Hsing; Michael Alavanja; Laura Beane-Freeman; Mahboobeh Safaiean; Stephen J Chanock; Preetha Rajaraman Journal: Am J Epidemiol Date: 2011-09-13 Impact factor: 4.897
Authors: Bhuma Krishnamachari; Dora Il'yasova; Michael E Scheurer; Melissa L Bondy; Margaret Wrensch; Faith G Davis Journal: Cancer Causes Control Date: 2014-06-03 Impact factor: 2.506